Charles Schwab Investment Management Inc. Has $136,000 Stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Charles Schwab Investment Management Inc. reduced its holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 13.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,093 shares of the company’s stock after selling 11,484 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Actinium Pharmaceuticals were worth $136,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. The Manufacturers Life Insurance Company bought a new position in Actinium Pharmaceuticals in the 2nd quarter valued at $92,000. Renaissance Technologies LLC bought a new position in shares of Actinium Pharmaceuticals in the second quarter valued at about $142,000. Interchange Capital Partners LLC acquired a new position in Actinium Pharmaceuticals during the 3rd quarter worth about $37,000. Rhumbline Advisers lifted its position in Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after buying an additional 7,525 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Actinium Pharmaceuticals during the 2nd quarter worth about $356,000. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Stock Down 3.4 %

Shares of NYSE ATNM opened at $1.12 on Friday. Actinium Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $10.24. The company has a 50-day simple moving average of $1.57. The company has a market cap of $34.94 million, a price-to-earnings ratio of -0.81 and a beta of 0.07.

Analysts Set New Price Targets

A number of brokerages have weighed in on ATNM. Stephens reaffirmed an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Finally, StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Actinium Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).